ATNM

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Actinium Pharmaceuticals Inc

NYSE MKT | ATNM

1.41

USD

$0.00

(

0.00%

)

At Close (As of Nov 28, 2025)

$45.23M

Market Cap

-

P/E Ratio

-1.11

EPS

$2.41

52 Week High

$1.02

52 Week Low

HEALTHCARE

Sector

ATNM Chart

Recent Chart
Price Action

ATNM Technicals

Tags:

ATNM Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$811K
Total Revenue $0
Cost Of Revenue $811K
Costof Goods And Services Sold $811K
Operating Income -$42M
Selling General And Administrative $12M
Research And Development $30M
Operating Expenses $41M
Investment Income Net -
Net Interest Income $3.9M
Interest Income $3.9M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $811K
Income Before Tax -$38M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$38M
Comprehensive Income Net Of Tax -
Ebit -$38M
Ebitda -$37M
Net Income -$38M

Revenue & Profitability

Earnings Performance

ATNM Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $77M
Total Current Assets $75M
Cash And Cash Equivalents At Carrying Value $73M
Cash And Short Term Investments $73M
Inventory -
Current Net Receivables -
Total Non Current Assets $2.4M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $1.6M
Other Non Current Assets -
Total Liabilities $44M
Total Current Liabilities $8.1M
Current Accounts Payable $7.6M
Deferred Revenue -
Current Debt -
Short Term Debt $580K
Total Non Current Liabilities $36M
Capital Lease Obligations $1.6M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.6M
Other Current Liabilities -$580K
Other Non Current Liabilities -
Total Shareholder Equity $33M
Treasury Stock -
Retained Earnings -$376M
Common Stock $31K
Common Stock Shares Outstanding $30M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$33M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $811K
Capital Expenditures $11K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$11K
Cashflow From Financing $29M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$38M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$811K
Total Revenue $0
Cost Of Revenue $811K
Costof Goods And Services Sold $811K
Operating Income -$42M
Selling General And Administrative $12M
Research And Development $30M
Operating Expenses $41M
Investment Income Net -
Net Interest Income $3.9M
Interest Income $3.9M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $811K
Income Before Tax -$38M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$38M
Comprehensive Income Net Of Tax -
Ebit -$38M
Ebitda -$37M
Net Income -$38M

ATNM Profile

Actinium Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Actinium Pharmaceuticals, Inc. is a leading clinical-stage biopharmaceutical firm focused on developing cutting-edge therapies for bone marrow transplantation and adoptive cell therapies, with a primary emphasis on hematologic malignancies. Based in New York, the company is advancing its proprietary antibody-radionuclide conjugate platform, aimed at improving patient outcomes in both transplantation and cancer care. With a promising pipeline of therapeutic candidates and strategic collaborations, Actinium is well-positioned to tackle significant unmet medical needs in the oncology sector, making it a compelling prospect for institutional investors seeking innovation in biopharmaceuticals.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
VINE
+10.76%
$0.39
KTTA
+32.06%
$1.39
BITF
+11.91%
$3.10
IPG
-1.95%
$24.57
AXDX
-61.36%
$0.03
AMZE
+33.81%
$0.52
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-8.37%
$0.11
NVDA
-1.41%
$177.70
AMD
+3.93%
$214.24
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
TLRY
-19.39%
$0.83
SRM
+53.27%
$10.30
BIYA
+11.34%
$0.28
BYND
+2.00%
$1.04
TWOH
0.00%
$0.00
RUBI
-24.69%
$0.16
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
ITUB
+3.23%
$7.66
AFMD
-34.94%
$0.18
INTC
+5.13%
$38.70
APLD
+5.05%
$24.94
CLSK
+13.34%
$15.24
SNAP
+0.23%
$7.62
ADTX
+27.38%
$4.00
INHD
-6.51%
$0.21
MSTR
+2.00%
$175.64
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
KWM
+10.50%
$0.72
KSS
+7.49%
$24.10
ONMD
+55.63%
$2.21
KDLY
+7.20%
$0.49
NAKA
+7.20%
$0.49
ASST
+2.65%
$1.16
BMNU
+20.08%
$9.03
SAND
-6.04%
$12.12
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
NBIS
+6.53%
$94.69
CIFR
+6.60%
$20.41
BMNR
+6.77%
$33.89
C
+1.31%
$102.50
CHR
0.00%
$0.04
IREN
+0.12%
$48.51
NEHC
+8.33%
$5.07
SMX
+209.42%
$53.84
PLUG
+1.01%
$2.00
KEY
+0.16%
$18.40
NIO
+0.72%
$5.49
DEFT
+20.86%
$1.68
ONDS
-3.80%
$7.92
MPW
+2.12%
$5.77
WULF
+5.49%
$15.65
GOOG
-0.66%
$318.15
GOOGL
-0.33%
$318.88
MARA
+6.50%
$11.83
GPUS
+1.14%
$0.33
TSLA
+0.65%
$429.38
IBRX
+2.40%
$2.13
CCCS
+0.96%
$7.32
PYPL
+0.99%
$61.83
FL
-0.37%
$24.01
VALE
+0.75%
$12.60
CPRT
-0.79%
$38.75
FI
+0.06%
$60.80
AG
+8.35%
$14.63
VGFC
-1.90%
$0.05
VSA
-6.26%
$0.11
IVP
-9.92%
$0.12
CAN
+5.95%
$0.97
NLY
+1.02%
$22.67
WU
+0.58%
$8.67
CRCA
+19.42%
$4.39
CRCL
+7.47%
$78.07
CDE
+5.03%
$17.00
UAA
+2.66%
$4.62
SVMH
-14.58%
$0.73
AGL
+3.94%
$0.66
SPGC
-8.21%
$0.16
PSKY
+0.95%
$15.79
TMC
+11.40%
$6.49
SGHC
-6.74%
$10.93
TGI
+0.61%
$26.01
FNGB
+2.90%
$21.28
AMZN
+1.06%
$231.61
ABVE
+4.21%
$2.74
BURU
+5.26%
$0.23
MU
+1.62%
$234.01
FRO
-1.95%
$23.52
SOFI
+1.64%
$28.96
PLTR
+0.53%
$166.65
F
+0.50%
$13.25
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
VINE
+10.76%
$0.39
KTTA
+32.06%
$1.39
BITF
+11.91%
$3.10
IPG
-1.95%
$24.57
AXDX
-61.36%
$0.03
AMZE
+33.81%
$0.52
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-8.37%
$0.11
NVDA
-1.41%
$177.70
AMD
+3.93%
$214.24
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
TLRY
-19.39%
$0.83
SRM
+53.27%
$10.30
BIYA
+11.34%
$0.28
BYND
+2.00%
$1.04
TWOH
0.00%
$0.00
RUBI
-24.69%
$0.16
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
ITUB
+3.23%
$7.66
AFMD
-34.94%
$0.18
INTC
+5.13%
$38.70
APLD
+5.05%
$24.94
CLSK
+13.34%
$15.24
SNAP
+0.23%
$7.62
ADTX
+27.38%
$4.00
INHD
-6.51%
$0.21
MSTR
+2.00%
$175.64
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
KWM
+10.50%
$0.72
KSS
+7.49%
$24.10
ONMD
+55.63%
$2.21
KDLY
+7.20%
$0.49
NAKA
+7.20%
$0.49
ASST
+2.65%
$1.16
BMNU
+20.08%
$9.03
SAND
-6.04%
$12.12
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
NBIS
+6.53%
$94.69
CIFR
+6.60%
$20.41
BMNR
+6.77%
$33.89
C
+1.31%
$102.50
CHR
0.00%
$0.04
IREN
+0.12%
$48.51
NEHC
+8.33%
$5.07
SMX
+209.42%
$53.84
PLUG
+1.01%
$2.00
KEY
+0.16%
$18.40
NIO
+0.72%
$5.49
DEFT
+20.86%
$1.68
ONDS
-3.80%
$7.92
MPW
+2.12%
$5.77
WULF
+5.49%
$15.65
GOOG
-0.66%
$318.15
GOOGL
-0.33%
$318.88
MARA
+6.50%
$11.83
GPUS
+1.14%
$0.33
TSLA
+0.65%
$429.38
IBRX
+2.40%
$2.13
CCCS
+0.96%
$7.32
PYPL
+0.99%
$61.83
FL
-0.37%
$24.01
VALE
+0.75%
$12.60
CPRT
-0.79%
$38.75
FI
+0.06%
$60.80
AG
+8.35%
$14.63
VGFC
-1.90%
$0.05
VSA
-6.26%
$0.11
IVP
-9.92%
$0.12
CAN
+5.95%
$0.97
NLY
+1.02%
$22.67
WU
+0.58%
$8.67
CRCA
+19.42%
$4.39
CRCL
+7.47%
$78.07
CDE
+5.03%
$17.00
UAA
+2.66%
$4.62
SVMH
-14.58%
$0.73
AGL
+3.94%
$0.66
SPGC
-8.21%
$0.16
PSKY
+0.95%
$15.79
TMC
+11.40%
$6.49
SGHC
-6.74%
$10.93
TGI
+0.61%
$26.01
FNGB
+2.90%
$21.28
AMZN
+1.06%
$231.61
ABVE
+4.21%
$2.74
BURU
+5.26%
$0.23
MU
+1.62%
$234.01
FRO
-1.95%
$23.52
SOFI
+1.64%
$28.96
PLTR
+0.53%
$166.65
F
+0.50%
$13.25
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.